4-硼苯磺酰胺叔丁酯 | 208516-15-8

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-硼苯磺酰胺叔丁酯
• 中文别名: 4-(叔丁基磺酰胺基)苯硼酸
• 英文名称: 4-(N-tert-butylsulfamoyl)phenylboronic acid
• 英文别名: N-tert-butyl 4-boronobenzenesulfonamide；4-(tert-butylaminosulphonyl)benzeneboronic acid；tert-butyl 4-boronobenzenesulfonamide；4-t-butylaminosulfonyl-phenylboronic acid；4-(tert.-butylsulfamoyl)-phenylboronic acid；4-t-butylaminosulfonylbenzene boronic acid；4-tert-butylsulfamoyl-benzeneboronic acid；[4-(tert-butylsulfamoyl)phenyl]boronic acid
• CAS: 208516-15-8
• 化学式: C₁₀H₁₆BNO₄S
• 分子量: 257.118
• InChiKey: BBTSLOMTYZIGGC-UHFFFAOYSA-N

物化性质

• 熔点：
  128-132
• 沸点：
  427.2±55.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.56
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  95
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2935009090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
t-Butyl 4-boronobenzenesulfonamide
Product Name:
Synonyms: 4-t-Butylsulfamoylphenylboronic acid; 4-t-Butylaminosulfonylphenylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
t-Butyl 4-boronobenzenesulfonamide
Ingredient name:
CAS number: 208516-15-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H16BNO4S
Molecular weight: 257.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-硼苯磺酰胺叔丁酯 以 三氟乙酸 、 乙醚 为溶剂， 反应 15.0h， 生成 4-(氨基磺酰基)苯硼酸
  参考文献：
  名称：

  2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2

  摘要：

  本发明涵盖了式I的新化合物，以及治疗环氧合酶-2介导的疾病的方法，包括向需要此类治疗的患者施用式I化合物的非毒性治疗有效量。##STR1## 本发明还涵盖了治疗环氧合酶-2介导的疾病的某些药物组合物，其中包括式I的化合物。

  公开号：

  US06046217A1

文献信息

• Discovery of BNC375, a Potent, Selective, and Orally Available Type I Positive Allosteric Modulator of α7 nAChRs
  作者：Andrew J. Harvey、Thomas D. Avery、Laurent Schaeffer、Christophe Joseph、Belinda C. Huff、Rajinder Singh、Christophe Morice、Bruno Giethlen、Anton A. Grishin、Carolyn J. Coles、Peter Kolesik、Stéphanie Wagner、Emile Andriambeloson、Bertrand Huyard、Etienne Poiraud、Dharam Paul、Susan M. O’Connor

  DOI：10.1021/acsmedchemlett.9b00001

  日期：2019.5.9

  whereas Type II PAMs both increase channel response and delay receptor desensitization. Both Type I and Type II PAMs are reported in literature, but there are limited reports describing their structure-kinetic profile relationships. Here, we report a novel class of compounds with either Type I or Type II behavior that can be tuned by the relative stereochemistry around the central cyclopropyl ring: for example

  就其对通道动力学的影响而言，α7nAChRs的正变构调节剂（PAM）可能具有不同的特性。I型PAM会放大对乙酰胆碱的峰通道响应，但似乎不会影响通道脱敏动力学，而II型PAM会增加通道响应并延迟受体脱敏。I型和II型PAM均在文献中进行了报道，但很少有报道描述它们的结构动力学轮廓关系。在这里，我们报告了一类具有I型或II型行为的新型化合物，可以通过围绕中央环丙基环的相对立体化学进行调节：例如（R，R）-13（BNC375）及其具有RR立体化学的类似物I型PAM位于中央环丙基环周围，而具有SS立体化学的同一系列化合物（例如，（S，S）-13）是使用膜片钳电生理学测量的II型PAM。通过改变苯胺环上的取代基可实现对动力学的进一步精细控制：通常，苯胺被强吸电子基团取代会降低这些化合物的II型特性。我们通过结构活性优化工作发现了BNC375，这是一种具有良好CNS-药物样性质和临床候选潜力的小分子。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014135495A1

  公开（公告）日：2014-09-12

  The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

  本发明公开了化合物的结构式I：其中结构式I中的变量如本文所述。还公开了含有这些化合物的药物组合物，以及使用结构式I中的化合物预防或治疗HCV感染的方法。
• Synthesis of three 18F-labelled cyclooxygenase-2 (COX-2) inhibitors based on a pyrimidine scaffold
  作者：Ole Tietz、Sai Kiran Sharma、Jatinder Kaur、Jenilee Way、Alison Marshall、Melinda Wuest、Frank Wuest

  DOI：10.1039/c3ob41935e

  日期：——

  Cyclooxygenase (COX) is the key enzyme within the complex conversion of arachidonic acid into prostaglandins (PGs). Inhibitors of this enzyme represent a particularly promising class of compounds for chemoprevention and cancer therapy. The experimental data on the involvement of COX isoform COX-2 in tumour development and progression, as well as the observed overexpression of COX-2 in a variety of human cancers provide the rationale for targeting COX-2 for molecular imaging and therapy of cancer. A series of trifluoromethyl-substituted pyrimidines was prepared as a novel class of selective COX-2 inhibitors, based on the lead structure 1a. All compounds were tested in cyclooxygenase (COX) assays in vitro to determine COX-1 and COX-2 inhibitory potency and selectivity. Molecular docking studies using the catalytic site of COX-1 and COX-2, respectively, provided complementary theoretical support for the obtained experimental biological structure–activity relationship data of three highly potent and selective fluorobenzyl-containing COX-2 inhibitors. Selected fluorobenzyl-substituted pyrimidine derivatives were further developed as 18F-labelled radiotracers ([18F]1a, [18F]2a, [18F]3a). Radiotracers [18F]1a and [18F]2a were radiolabelled using 4-[18F]fluorobenzylamine ([18F]FBA) as a building block. Radiotracer [18F]3a was radiofluorinated directly using a nucleophilic aromatic substitution reaction with no-carrier-added (n.c.a.) [18F]fluoride on an iodylaryl compound as a labelling precursor.

  环氧合酶（COX）是将花生四烯酸转化为前列腺素（PGs）的复杂过程中的关键酶。这种酶的抑制剂是一类特别有前景的化合物，适用于化学预防和癌症疗法。COX亚型COX-2参与肿瘤发生和发展的实验数据，以及在人类多种癌症中观察到的COX-2过表达，为靶向COX-2进行癌症的分子成像和治疗提供了理论依据。以先导结构1a为基础，合成了一系列三氟甲基取代的嘧啶化合物，作为新型选择性COX-2抑制剂。所有化合物均在体外的环氧合酶（COX）测定中进行了测试，以确定COX-1和COX-2的抑制效力和选择性。使用COX-1和COX-2的催化位点进行的分子对接研究，为获得的三种高效且选择性强的含氟苄基COX-2抑制剂的实验生物结构–活性关系数据提供了补充的理论支持。选择的氟苄基取代嘧啶衍生物进一步开发为18F标记的放射示踪剂（[18F]1a, [18F]2a, [18F]3a）。放射示踪剂[18F]1a和[18F]2a使用4-[18F]氟苄胺（[18F]FBA）作为构建块进行放射标记。放射示踪剂[18F]3a则通过与无载体添加（n.c.a.）的[18F]氟化物在碘芳基化合物上进行亲核芳香取代反应直接进行放射氟化。
• Facile Synthesis of Substituted 5-Amino- and 3-Amino-1,2,4-Thiadiazoles from a Common Precursor
  作者：Paul M. Wehn、Paul E. Harrington、John E. Eksterowicz

  DOI：10.1021/ol902371y

  日期：2009.12.17

  A novel approach to the synthesis of substituted 5-amino- and 3-amino-1,2,4-thiadiazoles beginning from a common precursor has been achieved. Derivatization by palladium-catalyzed Suzuki−Miyaura coupling enables the rapid preparation of analogs around this pharmaceutically relevant core. FMO calculations rationalize the observed chemoselectivity for coupling at chlorine.

  已经实现了从常见的前体开始合成取代的5-氨基-和3-氨基-1,2,4-噻二唑的新颖方法。通过钯催化的Suzuki-Miyaura偶联进行的衍生化作用可以围绕该药学相关核心快速制备类似物。FMO计算可合理化所观察到的在氯上偶合的化学选择性。
• A divergent protocol for solid-phase synthesis of highly substituted Bi-aryl furan derivatives
  作者：Yongxin Han、Amélie Roy、André Giroux

  DOI：10.1016/s0040-4039(00)00907-2

  日期：2000.7

  A versatile protocol for the solid-phase synthesis of highly substituted furan derivatives is discussed. This approach employs zincate 1 as the scaffold followed by sequential palladium-catalyzed cross-coupling reactions as the C–C bond-formation step. This methodology allows convenient modification of the furan core in three dimensions, giving rise to structurally diverse derivatives with overall

  讨论了用于高度取代的呋喃衍生物的固相合成的通用协议。这种方法采用锌酸盐1作为支架，然后依次进行钯催化的交叉偶联反应作为C–C键形成步骤。这种方法可以方便地在三个方面对呋喃核进行修饰，从而产生结构多样的衍生物，总体上具有良好的化学纯度和产率。